A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy.

PubWeight™: 1.14‹?› | Rank: Top 10%

🔗 View Article (PMC 3328656)

Published in Cancer Res on February 24, 2012

Authors

Hyun-Il Cho1, Eduardo Reyes-Vargas, Julio C Delgado, Esteban Celis

Author Affiliations

1: Immunology Program, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA.

Articles citing this

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18

Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res (2014) 0.90

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway. Oncoimmunology (2014) 0.87

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc Natl Acad Sci U S A (2014) 0.87

The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site. Mol Ther (2014) 0.86

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother (2015) 0.84

Harnessing the Microbiome to Enhance Cancer Immunotherapy. J Immunol Res (2015) 0.79

An optimized peptide vaccine strategy capable of inducing multivalent CD8(+) T cell responses with potent antitumor effects. Oncoimmunology (2015) 0.78

Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. Cancer Immunol Res (2016) 0.77

Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunol Immunother (2014) 0.76

MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth. Immun Inflamm Dis (2014) 0.75

The Immunotherapy Roadmap. Clin Cancer Res (2015) 0.75

miR-155 releases the brakes on antitumor T cells. Oncoimmunology (2015) 0.75

Articles cited by this

Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol (1974) 11.12

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13

Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60

Homeostasis of naive and memory T cells. Immunity (2008) 7.48

Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science (2006) 6.38

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59

New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57

Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24

Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94

The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37

The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol (1993) 4.35

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother (2010) 2.30

Peripheral tolerance of CD8 T lymphocytes. Immunity (2005) 2.21

Mechanisms maintaining peripheral tolerance. Nat Immunol (2009) 2.14

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13

Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol (1996) 2.11

The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol (1994) 1.93

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82

A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol (2003) 1.81

B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80

Homeostatic proliferation and survival of naïve and memory T cells. Eur J Immunol (2009) 1.71

Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60

Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res (2009) 1.49

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol (2006) 1.44

Adoptive cell transfer therapy. Semin Oncol (2007) 1.44

The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol (2003) 1.33

Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) (2002) 1.32

Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol (2006) 1.31

Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res (2009) 1.26

Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother (1999) 1.25

Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol (1993) 1.20

Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A (2008) 1.16

In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res (2008) 1.14

Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother (2008) 1.13

Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc (2002) 1.05

Perforin and its role in T lymphocyte-mediated cytolysis. Experientia (1992) 0.80

Articles by these authors

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97

Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20

Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev (2008) 2.07

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01

Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71

Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49

Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res (2009) 1.49

Endoplasmic reticulum aminopeptidase associated with antigen processing defines the composition and structure of MHC class I peptide repertoire in normal and virus-infected cells. J Immunol (2010) 1.46

Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol (2011) 1.45

Prognostic factors and risk stratification in early mycosis fungoides. Leuk Lymphoma (2013) 1.42

PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest (2009) 1.37

Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res (2003) 1.32

Interferon γ limits the effectiveness of melanoma peptide vaccines. Blood (2010) 1.26

A community-based tuberculosis program in Cambodia. JAMA (2004) 1.21

Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol (2002) 1.21

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16

Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res (2003) 1.16

Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol (2004) 1.15

Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res (2002) 1.15

In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res (2008) 1.14

PRDM1/Blimp-1 controls effector cytokine production in human NK cells. J Immunol (2010) 1.11

Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol (2009) 1.11

Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest (2013) 1.08

Retracted B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. Proc Natl Acad Sci U S A (2005) 1.07

Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest (2002) 1.07

Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc (2002) 1.05

Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol (2008) 1.03

Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res (2002) 1.02

Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. Cancer Immunol Immunother (2008) 1.02

BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother (2012) 1.02

TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother (2012) 1.01

Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res (2002) 1.01

Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res (2002) 1.00

T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol (2006) 1.00

Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer (2007) 1.00

Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Hum Vaccin Immunother (2013) 0.98

Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. J Virol (2012) 0.98

Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol (2006) 0.97

Large scale mass spectrometric profiling of peptides eluted from HLA molecules reveals N-terminal-extended peptide motifs. J Immunol (2008) 0.96

Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J Immunol (2013) 0.96

Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood (2002) 0.95

Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J Heart Lung Transplant (2009) 0.93

Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res (2012) 0.90

Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res (2014) 0.90

ERAAP and tapasin independently edit the amino and carboxyl termini of MHC class I peptides. J Immunol (2013) 0.90

Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol (2014) 0.89

Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation. Clin Cancer Res (2003) 0.89

Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck (2012) 0.88

Penaeus monodon tropomyosin induces CD4 T-cell proliferation in shrimp-allergic patients. Hum Immunol (2011) 0.88

Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res (2005) 0.87

Utility of characteristic QTOF MS/MS fragmentation for MHC class I peptides. J Proteome Res (2011) 0.87

Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clin Cancer Res (2002) 0.87

Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res (2007) 0.86

Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother (2005) 0.86

Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother (2005) 0.86

Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol Appl Pharmacol (2006) 0.86

Identification of naturally processed ligands in the C57BL/6 mouse using large-scale mass spectrometric peptide sequencing and bioinformatics prediction. Immunogenetics (2009) 0.85

T-cell epitope peptide vaccines. Expert Rev Vaccines (2004) 0.85

Identification and validation of shrimp-tropomyosin specific CD4 T cell epitopes. Hum Immunol (2013) 0.84

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother (2015) 0.84

Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J Transl Med (2011) 0.84

Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. Cancer Immunol Immunother (2010) 0.84

Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin Cancer Res (2005) 0.84

Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res (2008) 0.84

Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Drug Discov Today (2007) 0.83

Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2(180-188) peptides. Cancer Immunol Immunother (2012) 0.83

Direct cross-priming by th lymphocytes generates memory cytotoxic T cell responses. J Immunol (2005) 0.83

Antigen-independent acquisition of MHC class II molecules by human T lymphocytes. Int Immunol (2004) 0.83

Higher SLPI expression, lower immune activation, and increased frequency of immune cells in a cohort of Colombian HIV-1 controllers. J Acquir Immune Defic Syndr (2012) 0.83

Design of immunogenic and effective multi-epitope DNA vaccines for melanoma. Cancer Immunol Immunother (2011) 0.82

Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy. J Med Chem (2012) 0.81

Validation of cytomegalovirus immune competence assays for the characterization of CD8(+) T cell responses posttransplant. Clin Dev Immunol (2012) 0.81

CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. Cancer Immunol Immunother (2015) 0.81

Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res (2007) 0.81

Recognition of adult T-cell leukemia/lymphoma cells by CD4+ helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein. Clin Cancer Res (2004) 0.81

Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma. Cancer Immunol Immunother (2004) 0.81

Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. J Transl Med (2014) 0.80

Identification and characterization of a T-helper peptide from carcinoembryonic antigen. Clin Cancer Res (2004) 0.80

Specificity of EIA immunoassay for complement factor Bb testing. Clin Lab (2011) 0.80

Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53. Cancer Immunol Immunother (2014) 0.80

Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. Int J Cancer (2009) 0.80

Oral administration of PPC enhances antigen-specific CD8+ T cell responses while reducing IgE levels in sensitized mice. BMC Complement Altern Med (2009) 0.79

Binding of anti-HLA class I antibody to endothelial cells produce an inflammatory cytokine secretory pattern. J Clin Lab Anal (2009) 0.79

Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. Clin Vaccine Immunol (2009) 0.79

A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope. Cancer Immunol Immunother (2012) 0.79

In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma. J Pediatr Surg (2007) 0.78

In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes. Clin Cancer Res (2006) 0.78

Avoiding Tolerance Against Prostatic Antigens With Subdominant Peptide Epitopes. J Immunother (1991) (2001) 0.78

Overcoming doubts and other obstacles in the development of effective peptide-based therapeutic vaccines against cancer. Expert Rev Vaccines (2010) 0.78

Functional analysis of birch pollen allergen Bet v 1-specific regulatory T cells. J Immunol (2007) 0.78

Unpasteurized milk consumption and subsequent risk of cancer. Cancer Causes Control (2008) 0.78